Krieg AM: Toll-like receptor 9 (TLR9) agonists in the treatment o

Krieg AM: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008,27(2):161–167.PubMedCrossRef 4. Weiner GJ, Liu HM, BMS202 supplier Wooldridge JE, Dahle CE, Krieg AM: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997,94(20):10833–10837.PubMedCrossRef 5. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM: Human peripheral

blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001,166(4):2372–2377.PubMed 6. Hartmann G, Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000,164(2):944–953.PubMed 7. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995,374(6522):546–549.PubMedCrossRef 8. Kuo CC, Liang CM, Lai CY, Liang SM: Involvement of heat Selleck Rabusertib shock protein (Hsp) 90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J Immunol 2007,178(10):6100–6108.PubMed 9. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner selleck compound M, Poeck H, Hartmann

E, Jox R, Giese T, Emmerich B, Endres S: B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005,11(4):1490–1499.PubMedCrossRef 10. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W: Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010,115(24):5041–5052.PubMedCrossRef 11. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G: Modulation of malignant B cell activation and apoptosis

by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002,72(1):83–92.PubMed 12. Rubenstein J, Ferreri AJ, Pittaluga S: Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma 2008,49(Suppl 1):43–51.PubMedCrossRef 13. Donnou S, Galand C, Touitou V, Sautes-Fridman C, Fabry Z, Fisson S: Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol 2012, 2012:701–704. 14. Houot R, Levy R: T-cell modulation combined with intratumoral CpG cures lymphoma PTK6 in a mouse model without the need for chemotherapy. Blood 2009,113(15):3546–3552.PubMedCrossRef 15. Weiner GJ: The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000,68(4):455–463.PubMed 16. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R: Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007,179(4):2493–2500.PubMed 17. Jahrsdorfer B, Weiner GJ: CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008,3(1):27–32.

Comments are closed.